What is claimed is:

1. ~~A method of treating a disease chosen from membranous nephropathy (MN), IgG4-related diseases (IgG4-RD), and antiphospholipid syndrome (APS) in a mammal in need thereof, comprising administering to said mammal~~ Use of a pharmaceutical composition comprising:

a compound chosen from (E) isomer, (Z) isomer, and a mixture of (E) and (Z) isomers of 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile; and/or

a pharmaceutically acceptable salt of any of the foregoing compounds; and

a pharmaceutically acceptable carrier or excipient, in the manufacture of a medicament for treating a disease chosen from membranous nephropathy (MN), IgG4-related diseases (IgG4-RD), and antiphospholipid syndrome (APS) in a mammal.

2. The ~~method~~ use of claim 1, wherein the disease is acute.

3. The ~~method~~ use of claim 1 or 2, wherein the disease is an IgG4-RD disease flare.

4. The ~~method~~ use of any one of claims 1-3, wherein the pharmaceutical composition is to be orally administered.

5. The ~~method~~ use of any one of claims 1-4, wherein the pharmaceutical composition is to be administered daily.

6. The ~~method~~ use of any one of claims 1-5, wherein the pharmaceutical composition is to be orally administered daily.

7. The ~~method~~ use of any one of claims 1-6, wherein the pharmaceutical composition is to be administered in place of an immunosuppressive therapy.

8. The ~~method~~ use of any one of claims 1-7, wherein the pharmaceutical composition is to be administered in place of a corticosteroid therapy.

9. The ~~method~~ use of any one of claims 1-6, wherein the pharmaceutical composition is to be administered in combination with an immunosuppressive therapy.

10. The ~~method~~ use of any one of claims 1-6, wherein the pharmaceutical composition is to be administered in combination with a corticosteroid therapy.

11. The ~~method~~ use of any of claims 1-6 or 8-10, wherein the pharmaceutical composition is to be administered in combination with a noncorticosteroidal immunosuppressive and/or anti-inflammatory agent.

12. The ~~method~~ use of any one of claims 1 or 4-6, wherein the pharmaceutical composition is to be administered in place of an immunosuppressive maintenance therapy.

13. The ~~method~~ use of any one of claims 1 or 4-6, wherein the pharmaceutical composition is to be administered in place of a corticosteroid maintenance therapy.

14. The ~~method~~ use of any one of claims 1, 2, or 4-6, wherein the pharmaceutical composition is to be administered in combination with an immunosuppressive maintenance therapy.

15. The ~~method~~ use of any one of claims 1, 2, or 4-6, wherein the pharmaceutical composition is to be administered in combination with a corticosteroid maintenance therapy.

16. The ~~method~~ use of any one of claims 13-15, wherein the pharmaceutical composition is to be administered in combination with a noncorticosteroidal immunosuppressive and/or anti-inflammatory agent.

17. The ~~method~~ use of any one of claims 1-16, wherein the pharmaceutical composition comprises a compound which is a substantially pure (E) or (Z) isomer of 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile, and/or

a pharmaceutically acceptable salt of said compound; and

a pharmaceutically acceptable carrier or excipient.

18. The ~~method~~ use of any one of claims 1-17, wherein at least about 85% w/w of 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile or at least about 85% w/w of a pharmaceutically acceptable salt of 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile is the (E) isomer.

19. The ~~method~~ use of any one of claims 1-18, wherein the mammal is a human.

20. The ~~method~~ use of any one of claims 1-19, wherein the disease is an IgG4-related disease characterized by an IgG4-RD Responder Index (RI) greater than or equal to 2 in at least one organ system.

21. The ~~method~~ use of any one of claims 1-20, wherein the disease is an IgG4-related disease characterized by a serum IgG4 concentration greater than 1.5 times the upper limit of normal.

22. The ~~method~~ use of any one of claims 1-21, wherein the disease is chosen from IgG4-related sialadenitis, IgG4-related ophthalmic disease (IgG4-ROD), IgG4-related pharyngitis, IgG4-related thyroid disease, IgG4-related hypophysitis, IgG4-related pachymeningitis, IgG4-related leptomeningitis, IgG4-related pancreatitis, IgG4-related lung disease, IgG4-related pleuritis, IgG4-related hepatopathy, IgG4-related sclerosing cholangitis, IgG4-related cholecystitis, IgG4-related aortitis, IgG4-related periaortitis, IgG4-related periarteritis, IgG4-related pericarditis, IgG4-related mediastinitis, IgG4-related retroperitoneal fibrosis, IgG4-related mesenteritis, IgG4-related mastitis, IgG4-related kidney disease (IgG4-RKD), IgG4-related prostatitis, IgG4-related perivasal fibrosis, IgG4-related paratesticular pseudotumor, IgG4-related epididymo-orchitis, IgG4-related lymphadenopathy, IgG4-related skin disease, and IgG4-related perineural disease, or flares of any of the preceding IgG4-related diseases.

23. The ~~method~~ use of claim 1, wherein the pharmaceutical composition is to be administered in combination with an active pharmaceutical ingredient chosen from interferon alpha, interferon gamma, cyclophosphamide, tacrolimus, mycophenolate mofetil,

methotrexate, dapsone, sulfasalazine, azathioprine, an anti-CD20 agent, an anti-TNF alpha agent, an anti-IL-4 agent toward ligand or its receptors, an anti-IL-6 agent toward ligand or its receptors, an anti-IL-12 agent to ligand or its receptors, an anti-IL-17 agent to ligand or its receptors, an anti-IL-1 agent to ligand or its receptors, an anti-IL-2 agent to ligand or its receptors, an anti-IL-23 agent to ligand or its receptors, an anti-IL-12/23 agent to ligand or receptors, an anti-CD2 agent, an anti-CD3 agent, an anti-CD80/86 agent, an anti-sphingosine-1-phosphate receptor agent, an anti-C5 agent, an anti-mTOR agent, an anti-calcineurin agent, an anti-BAFF/BlyS agent, leflunomide, and teriflunomide.

24. The ~~method~~ use of claim 1, wherein the pharmaceutical composition is to be administered in combination with rituximab, dupilumab, ofatumumab, obinutuzumab, or veltuzumab, or a biosimilar version of any of the foregoing.

25. The ~~method~~ use of any one of claims 1-6, 9-11, or 14-24, wherein the mammal is treatment naïve with respect to a immunosuppressive therapy.

26. The ~~method~~ use of any one of claims 1-6, 9-11, or 14-24, wherein the mammal is treatment naïve with respect to any immunosuppressive therapy.

27. The ~~method~~ use of any one of claims 1-24, wherein the mammal has been previously treated with an immunosuppressive therapy.